SCHEMBL5217439

SCHEMBL5217439

Cc1ccc(C)c(-n2cc(-c3cnc4ccccc4n3)cn2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.53
JAK2 O60674 2/20 0.46
RAB9A P51151 7/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
KDR P35968 2/20 0.43
PDGFRB P09619 1/20 0.43
FLT3 P36888 1/20 0.43
FGFR3 P22607 1/20 0.41
MAPT P10636 6/20 0.41
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
ALDH1A1 P00352 3/20 0.41
ALOX12 P18054 1/20 0.41
MAPK10 P53779 1/20 0.41
ATM Q13315 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5219172 0.90 NPC1 (0.50) NPC1JAK2RAB9ASMN1; SMN2KDR
SCHEMBL5215401 0.88 NPC1 (0.51) NPC1JAK2RAB9ASMN1; SMN2KDR
SCHEMBL5217660 0.87 NPC1 (0.51) NPC1JAK2RAB9ASMN1; SMN2KDR
SCHEMBL5217878 0.86 MAPT (0.45) NPC1RAB9ASMN1; SMN2KDRPDGFRB
SCHEMBL5220308 0.86 NPC1 (0.49) NPC1JAK2RAB9ASMN1; SMN2KDR
SCHEMBL5215948 0.85 NPC1 (0.45) NPC1RAB9ASMN1; SMN2KDRPDGFRB
SCHEMBL8357642 0.82 NPC1 (0.50) NPC1JAK2RAB9ASMN1; SMN2KDR
SCHEMBL5219466 0.82 NPC1 (0.48) NPC1RAB9ASMN1; SMN2KDRPDGFRB
SCHEMBL5216003 0.81 NPC1 (0.62) NPC1JAK2RAB9ASMN1; SMN2KDR
SCHEMBL5215183 0.81 NPC1 (0.48) NPC1JAK2RAB9ASMN1; SMN2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C NPC1 4205/4885JAK2 1569/4885RAB9A 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.